Matt Maley, equity strategist at Miller Tabak + Co joins Yahoo Finance’s Alexis Christoforous and Brian Sozzi to discuss the markets and how investors should be investing during this time of market uncertainty and volatility....
When you're looking for the best stocks to buy after the coronavirus crash, look for those with surging relative strength lines. The RS line measures a stock's price performance vs. the S&P 500. So the stocks with strong RS lines deserve a spot on your watchlist as we wait for a new market uptrend. Coronavirus crash play Zoom Video is among potential stocks to buy in the next uptrend given its strong technical action....
(Bloomberg) -- Carnival Corp., the largest player in a cruise industry reeling from the effects of the coronavirus, said it expects a loss this fiscal year and is taking steps to improve liquidity.The efforts include cutting investments and expenses and looking for additional financing, Carnival said in a statement Monday. The company said it provided notice on Friday to borrow about $3 billion for six months under an existing credit facility, fully drawing down the credit line to meet working capital, general corporate and other needs.The spread of the coronavirus has made it impossible to project earnings, the company said, but it expects to have a loss in the year ending Nov. 30.The cruise industry has been among the hardest hit in the world by the virus. On Friday, President Donald Trump tweeted that he had asked U.S.-based cruise lines to suspend voyages to halt disease transmission at sea. The move...
For the first time in at least 10 years, there is more insider buying than insider selling on Wall Street.Last week, company insiders purchased an aggregate $682.8 million in stock as the market sold off, according to InsideArbitrage. That buying was up from just $278.6 million in the previous week and outpaced total insider selling of $668.5 million.While insider buying may seem like a bullish signal on the surface, InsiderArbitrage founder Asif Suria said Sunday that Wall Street insiders tend to be overly optimistic when it comes to their own companies."We have been bearish for several weeks now and have written about showing restraint despite the insiders stepping up their insider buying because insiders as a group generally tend to be optimistic about their own companies, sometime buy to 'signal' the market and like value investors often tend to be early," Suria said.Top Insider Buying Stocks InsiderArbitrage found the most insider...
Billionaire investor Ray Dalio, whose main Bridgewater Associates LP hedge fund fell sharply amid the coronavirus-led market rout, is concerned about the combination of zero interest rate policy and the growing health pandemic, he said in a note Monday. "I have been concerned that when the economic downturn would come, it would lead to hitting the 0% interest rate in an economic downturn with a lot of debt outstanding and big wealth and political gaps the way that configuration of events happened the 1930s," Dalio wrote. On Sunday, the U.S. Federal Reserve cut interest rates to a target range of 0% to 0.25%, its second emergency reduction in less than two weeks to help shore up the U.S. economy....
As the market’s volatility reaches new highs, investors are looking for a sign that its safe to invest given the current uncertainty in the markets. Matt Maley, equity strategist at Miller Tabak + Co joins The First Trade to discuss....
The novel coronavirus is dominating headlines around the world right now. But in Maxim Group's latest report on Inovio Pharmaceuticals (INO), COVID-19 merits hardly a mention. Turns out, Maxim loves this stock, but not only because of Coronavirus.In Maxim's note, analyst Jason McCarthy notes that "it's too early to tell" if Inovio is "a COVID-19 play." On the one hand, "Inovio has rapidly developed its DNA-based COVID-19 vaccine, INO-4800." Within just three hours of receiving its first sample of the virus's genetic sequence, Inovio already had the vaccine candidate prepared "using its DNA-based vaccine platform," and began "preclinical development."Like Novavax (NVAX) before it, Inovio also received a grant from Norway's Coalition for Epidemic Preparedness (CEPI) to fund development of the vaccine through "preclinical and" Phase 1 stages. Notably, Inovio's $9 million grant was approximately twice the size of the grant awarded to Novavax last week, and Inovio received a further $5...